Adheris FY26 Results

• Refreshed leadership team and migrated to new technology platform
• Reduced operating costs by 37% from FY25 to FY26
• FY26 revenue and profitability impacted by lower customer renewals
• Achieved cashflow break-even in Q4 FY26
• Ended FY26 with $9.5 million in cash and no debt

Adheris Health Limited has reported its full year results for the 12 months ended 30 June 2026 (FY26). The company refreshed its leadership team, migrated to a new technology platform, and reduced operating costs by 37%. Despite these efforts, FY26 revenue and profitability were impacted by lower customer renewals and lower bookings through the previous pharma budget cycle. The company achieved cashflow break-even in Q4 FY26 and ended the year with $9.5 million in cash and no debt. The calendar 2027 (CY27) pharma planning cycle is well underway, with close to 60% of current opportunity value in THRiV and digital engagement programs. The company expects decisions on the majority of the pipeline by December 2026.

FY26 revenue $34.0M, FY26 gross profit $14.6M, FY26 underlying EBITDA loss $16.5M

Adheris Health expects decisions on the majority of the CY27 pipeline by December 2026, with a focus on rebuilding the revenue base.